Articles tagged with Heart Failure
A new study found that customized digital alerts via an electronic health record system significantly increased the number of guideline-directed medications prescribed for heart failure patients. The alerts improved medication use by over a quarter of patients, translating to one medication addition per every 14 alerts received.
A global trial found that people with heart failure who received an annual flu shot had lower rates of pneumonia and hospitalization on a year-round basis. The study also revealed significant reductions in major cardiovascular events during peak flu season.
A study of 806 patients with heart failure found that reducing sodium intake improved symptoms such as swelling, fatigue, and coughing. However, it had no effect on rates of death, hospitalization, or emergency department visits. The researchers recommend a lower sodium intake limit for heart failure patients.
The SODIUM-HF trial found that reducing sodium intake for one year improved quality of life and slowed heart failure progression in patients. However, it did not significantly reduce major adverse events or hospitalizations. The study suggests that individualized recommendations may be beneficial for certain patients.
The new ACC/AHA/HFSA guideline redefines heart failure stages to focus on prevention, updating treatment options for people with symptomatic heart failure. It recommends blood pressure control, SGLT-2 inhibitor medicines, and healthy lifestyle habits to prevent HF risk factors from developing.
A study published in European Heart Journal found that serum sodium levels can help identify adults with a greater chance of experiencing heart disease. The research suggests that staying well-hydrated and consuming sufficient amounts of fluids throughout life may also reduce the risk of severe heart problems in the future.
A literature review found that spirituality can improve quality of life for heart failure patients, reducing depression and anxiety. Researchers are now working to develop a spirituality screening tool to identify patients at risk for spiritual distress.
A review article by UT Southwestern researchers highlights the root cause of heart failure with preserved ejection fraction (HFpEF), a condition affecting millions globally. Joint metabolic and immune dysfunction is proposed as the underlying mechanism, opening up possibilities for therapeutic targets.
A new CNIC study warns that mitochondrial therapeutic interventions can cause damage due to the mixing of mitochondrial DNAs from two distinct origins. This can lead to medium- and long-term health issues, including heart failure, pulmonary hypertension, and muscle loss.
Researchers at Lewis Katz School of Medicine at Temple University discover a molecular pathway driving maladaptive processes in heart failure, revealing the importance of GRK5's catalytic activity and nuclear presence. The study opens doors to new therapeutic strategies for treating this devastating condition.
Researchers found that chronic lactate exposure can lead to cellular disruptions, decreased fatty acid transport, and alterations of mitochondrial membranes, which may contribute to the development of heart failure and type 2 diabetes. The study suggests that lactate accumulation could be a major player in disease progression.
A study published in the American Heart Association's Circulation journal found that people with congenital heart defects who contracted COVID-19 were more likely to require intensive care or need a ventilator. The risk of severe illness was higher among those with additional health conditions, older adults, and men.
Researchers from NYITCOM are using a new imaging technique to study diabetic heart failure and its causes. They hope to develop new treatments by tracing how lysosomes, the body's defense system, are impaired in heart muscle cells.
Researchers found elevated plasma xanthine oxidase activity and more fragments of damaged mitochondrial DNA in Black adults with resistant hypertension compared to white adults. These findings suggest an important underlying cause of increased cardiovascular risk in Blacks with difficult-to-treat hypertension.
A large study found a significant link between salt-containing paracetamol and an increased risk of heart attacks, stroke, and death. Patients with high blood pressure who took sodium-containing paracetamol had a higher risk of cardiovascular disease and death compared to those taking non-sodium-containing paracetamol.
Researchers analyzed the gut microbiome of 1,241 middle-aged individuals and found that about half of the bacterial species were modified by drug treatment, while 75% of disturbances occurred in early stages of overweight and type 2 diabetes. The study suggests that an imbalanced gut microbiome may play a role in heart disease development
A study of 3099 older Italians found that increasing physical activity levels between 65-75 years old can lower cardiovascular disease risks in late old age. Maintaining an active lifestyle over time was associated with a 52% lower risk of cardiovascular disease among men.
A review published in Journal of Internal Medicine suggests that micronutrient supplementation could represent an effective treatment for heart failure. Micronutrients like iron, selenium, zinc, and coenzyme Q10 can impact cardiac cells' energy production, contributing to the disease.
A new 'bionic' pacemaker is being developed to restore the natural variability of the heartbeat, which has been found to improve cardiac output by 20%. This innovation could revolutionize the treatment of heart failure in New Zealand patients.
A Northwestern Medicine-led study found that a novel, minimally invasive cardiac implant device called an atrial shunt may benefit some patients with HFpEF. The device improves symptoms and quality of life by allowing blood to flow from the stiff left atrium to the normal right atrium.
A recent study published in Science Translational Medicine identified a novel causative gene, BAG5, for dilated cardiomyopathy, a leading cause of heart failure. The researchers found that mutations in this gene can lead to cardiomyopathy and found a potential treatment alternative using adeno-associated viruses (AAV) gene therapy.
A study by Baylor College of Medicine found that Rev-erbα/β in cardiomyocytes mediates a normal metabolic rhythm, enabling the cells to use lipids as energy during resting time. Removing Rev-erbα/β disrupts this rhythm, leading to progressive dilated cardiomyopathy and lethal heart failure.
The Cardiovascular Research Foundation (CRF) will host THT 2022 from February 1-2, 2022. The conference features new and emerging treatments for heart failure, including transcatheter approaches and innovative monitoring strategies.
Research from the University of Virginia Health System found that long-term use of ACE inhibitors and angiotensin receptor blockers can lead to hardened kidney vessels. The drugs, commonly prescribed for high blood pressure and heart failure, were associated with damage in both lab mice and humans.
Researchers have created an mRNA-based approach to reprogram immune cells to attack specific targets, with promising results in treating heart failure. The technique, which is simpler and more temporary than current CAR T cell technology, holds potential for addressing a range of fibrotic diseases.
Researchers have developed a novel strategy to enhance the reprogramming efficiency of human fibroblasts, significantly increasing their ability to become functional heart muscle. This approach uses endothelial cell plasticity to facilitate the desired change, offering new hope for patients with congestive heart failure.
A study by Indiana University School of Medicine researchers suggests that reperfusion therapy may not be as effective in halting muscle damage during heart attacks as previously thought. The team's findings indicate that internal bleeding within the heart muscle can continue to cause damage even after the blocked coronary artery is op...
Research finds GNAO1 expression affects calcium ion regulation in cardiomyocytes, leading to cardiac dysfunction and heart failure progression. Suppression of GNAO1 improves pathology in multiple mouse models.
A new Northwestern University study has derived and validated the first set of risk prediction models for lifetime risk of heart failure. The models can identify individuals at greatest risk, especially among young adults, allowing physicians to start prevention measures sooner.
An extensive study of over 400,000 individuals found no association between total alcohol consumption and ventricular arrhythmias, contradicting the traditional Holiday Heart Syndrome. Higher spirit intake was linked to an increased risk of ventricular arrhythmias, but not SCDs.
Researchers discovered that mechanical forces guide cell development, influencing gene expression and potentially leading to pathologies like heart disease. The findings could inspire advances in engineering authentic artificial tissue for medical applications.
A case report highlights the limitations of remote monitoring in detecting premature battery depletion in recalled pacemakers, leading to urgent device replacement. The cases emphasize the importance of closer monitoring and prophylactic generator changes in patients with high-risk devices.
A new study by Kaiser Permanente researchers has found that people with HIV are at higher risk of developing heart failure than those without the condition. The study identified significant differences in heart failure risk among various demographics, including age, sex, and ethnicity.
Researchers found a rare genetic mutation in Black Americans is associated with an earlier onset of heart failure and a higher risk of hospitalization. The study suggests that early screening for the mutation could lead to faster treatment and improved outcomes for this vulnerable group.
Researchers at the Max Delbrück Center have developed a therapeutic agent to improve treatment of heart failure with preserved ejection fraction. The new approach targets alternative splicing in cardiac disease, using antisense oligonucleotides to stabilize sensitive molecules and trigger desired response.
The new research center aims to develop a comprehensive understanding of heart failure with preserved ejection fraction (HFpEF) and improve treatment options. The researchers will study the underlying causes, molecular mechanisms, and effects on the cardiovascular system.
A new meta-analysis published in the European Journal of Preventive Cardiology suggests that Sodium-glucose co-transporter-2 (SGLT2) inhibitors can improve outcomes for heart failure patients with preserved ejection fraction. The medication has been shown to reduce the risk of death from heart-related causes and hospitalization by 22%.
A recent study published by the European Society of Cardiology found that aspirin use is associated with a 26% raised risk of heart failure in individuals with at least one predisposing factor for the condition. This includes factors such as smoking, obesity, high blood pressure, and cardiovascular disease.
A University at Buffalo study explores how social and economic characteristics influence hospital readmissions and health inequity in the US. The research found that patients with lower household income, male gender, or treated in urban hospitals have a higher risk of being readmitted within a month of discharge.
A study found that stem cell therapy reduced the number of heart attacks, strokes, and deaths among people with chronic heart failure, especially those with high levels of inflammation. However, hospitalization rates did not decrease despite the treatment, according to researchers from the American Heart Association.
A randomized placebo-controlled trial found canagliflozin improved symptoms, function, and quality of life for patients with heart failure. The study used a virtual approach, demonstrating the success of decentralized clinical trials.
A recent study published at the American Heart Association Scientific Sessions 2021 found that adults treated with empagliflozin during hospitalization for acute heart failure experienced increased survival, lower risk of re-hospitalization, and improved quality of life. The medication, originally used to treat type 2 diabetes, has bee...
Researchers at the Texas Heart Institute have made significant breakthroughs in treating persistent heart failure with a novel stem cell therapy. The phase 3 clinical trial results show that this treatment has the potential to alter the natural history of heart disease, reducing hospitalizations and improving patient outcomes.
A new study led by University of Minnesota Medical School researcher Xavier Revelo found that macrophages play a role in protecting the heart after injury. The research team discovered a large increase in cardiac macrophages early in response to a cardiac injury similar to high blood pressure.
Scientists discovered an important protective response in the heart that can prevent excessive scarring after a heart attack. The study found that this reactive response can limit cardiac fibrosis by preventing oxidant build-up in heart cells, potentially leading to new therapies to repair scarring damage.
A new study finds that genetic testing for cardiomyopathies and arrhythmias simultaneously can detect conditions more accurately than single-condition tests. This leads to better diagnosis and treatment options, such as targeted therapies and monitoring devices.
Despite Medicare's expanded coverage, only less than 10% of eligible adults with heart failure enrolled in cardiac rehabilitation between 2014 and 2021. This low enrollment rate is attributed to various barriers, including insurance coverage and CMS participation criteria.
A study suggests sacubitril/valsartan is no better than valsartan alone in patients with severe heart failure, but may be slightly safer. The treatment showed no improvement in biomarker levels or clinical outcomes for sickest patients.
Researchers found that slow release of TT-10 from nanoparticles improved heart function after a heart attack, accompanied by increased cardiomyocyte proliferation and smaller infarct size. The study suggests that PLGA nanoparticles could be used to improve treatment administration efficiency for cardiovascular drugs.
Researchers discovered a mechanism that could prove useful in treating heart failure with preserved ejection fraction (HFpEF), a common and hard-to-treat condition. The new approach reduces exposure to increased cardiac stiffness, which is associated with lower-filling pressures inside the heart chambers.
A new AI-based computer algorithm created by Mount Sinai researchers can identify subtle changes in electrocardiograms to predict heart failure. The algorithm was 94% accurate at predicting healthy ejection fractions and 87% accurate at detecting weakened hearts, offering a promising alternative to traditional diagnosis methods.
A study of 7,512 pregnancies in women with congenital heart disease found no maternal deaths, but more health complications for mothers and babies compared to a control group. Babies born to CHD mothers had an increased risk of stillbirths, low birthweight, and major visible abnormalities.
The ACHIEVE GREATER Center aims to reduce cardiometabolic health disparities by implementing a proactive approach using community health workers and pharmacists. The center will use collaborative care, PAL2, to address multiple domains of influence contributing to disparate health outcomes in the Black population.
A new study published in the Journal of the American Heart Association found that long-term exposure to air pollution and road traffic noise may be associated with an increased risk of developing heart failure. The correlation appears to be greater in people who are former smokers or have high blood pressure.
A UCL-led research team has discovered a new gene causing hypertrophic cardiomyopathy, an inherited heart condition. The study found that variants in the ALPK3 gene are responsible for 1-2% of adults with the condition, affecting approximately 1,250-2,500 people in the UK.
Researchers at Ohio State University found that cancer can cause cardiac dysfunction due to the presence of free radicals, which were reversed by specific antioxidants in fruit flies and mice with tumors. The study suggests a potential new approach to treating heart problems in cancer patients.
A study shows haemodynamic guided management may reduce heart failure hospitalisations in patients with earlier stage heart failure, even before the COVID-19 pandemic. The trial enrolled 1,000 patients with NYHA class II–IV heart failure and found a 17% reduction in heart failure hospitalisations.
The EMPEROR-Preserved trial found that empagliflozin reduced the risk of a composite of cardiovascular death or hospitalisation for heart failure in patients with heart failure and a preserved ejection fraction. The study showed that empagliflozin was effective across all prespecified subgroups, including those with or without diabetes.
A large clinical trial has identified empagliflozin as a treatment option for heart failure with preserved ejection fraction, reducing risk of hospitalization or death by 21 percent. The drug also showed fewer symptoms and mild side effects.
A pooled analysis of two trials found that empagliflozin reduced the risk of cardiovascular death or hospitalisation for heart failure patients, regardless of ejection fraction. The drug also showed benefits in reducing major renal outcomes, particularly at lower ejection fractions.